Intensity Therapeutics, Inc. (NasdaqCM: INTS)
Health Care · Biotechnology · US
$4.86
+22.72% today · -47.9% 1Y
Intensity Therapeutics, Inc. (NasdaqCM: INTS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.93M and employs 16 people.
Over the last twelve months the share price has lost 47.9%, trading between 3.51 and 43.50.
Tweenvest scores Intensity Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
INTS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.80
- Dividend yield
- —
- Beta (5Y)
- 3.03
- 52-week high
- $43.50
- 52-week low
- $3.51
- Avg volume (3M)
- —
- Shares outstanding
- 3.26M
- Employees
- 16
- Next earnings
- —
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
- Founded
- 2012
- Listed since
- Jun 30, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.